Mining The Data: WellPoint Stresses Need For Context In Safety Surveillance
This article was originally published in The Pink Sheet Daily
Executive Summary
WellPoint is exploring ways to more accurately identify adverse events as it builds a drug safety monitoring system.
You may also be interested in...
FDA Post-Market Safety Efforts Won’t Be Impacted By Sentinel In Near Term
FDA's Sentinel post-market safety monitoring project will augment, not replace, the agency's current repertoire of post-market activities and requirements for drugs, Center for Drug Evaluation and Research Director Janet Woodcock emphasized
WellPoint Drug Safety Monitoring System Expected To Go Live In Mid-2009
WellPoint is developing a post-marketing drug safety monitoring system that will be capable of drawing data from the 25 million members in its integrated medical and pharmacy insurance plans
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.